I described it in an earlier article as: Qelbree (viloxazine extended-release capsules) is Supernus' latest and greatest product. It was initially approved in 04/2021 to treat ADHD in pediatric ...

ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...

Supernus (SUPN) Pharmaceuticals announced that ... Qelbree is approved for use in patients ages 6 years and older with ADHD. Published first on TheFly – the ultimate source for real-time ...

By gaining a clear understanding of what ADHD is, common symptoms and how it affects people’s day to day lives, individuals can work with their doctors to choose the best course of action to suit ...

Qelbree® is a novel nonstimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Knight entered into an agreement in December 2023 with Supernus Pharmaceuticals ...